THC Lowers Eye Pressure but Falls Short for Glaucoma

For decades, researchers have been intrigued by an unusual effect of cannabis: THC can lower pressure inside the eye. That observation has fueled questions about whether cannabinoids could eventually play a role in glaucoma treatment.

Now, a 2026 published systematic review and meta-analysis has taken a closer look at the clinical evidence. The findings confirm that THC can reduce intraocular pressure (IOP), but they also reveal an important limitation that helps explain why cannabis has not become a standard glaucoma therapy. The findings suggest that the future of cannabinoid research may not be about smoking or consuming cannabis at all. Instead, scientists may be looking for ways to harness the eye’s cannabinoid receptors while avoiding the systemic and psychoactive effects associated with THC. Let’s dive into the research and what it means for the future of pharmaceutical grade cannabis therapies.

What Is Intraocular Pressure?

Intraocular pressure refers to the pressure created by fluid inside the eye. Maintaining healthy IOP is important because excessive pressure can contribute to damage of the optic nerve, the structure that carries visual information from the eye to the brain.

Glaucoma is a major cause of irreversible blindness worldwide. The disease affected an estimated 79.6 million people in 2020, with that number projected to reach 111.8 million by 2040. Lowering IOP is one of the central strategies used to manage glaucoma. Depending on the severity of the disease, treatment may aim for an IOP reduction of roughly 20% to 30%, with more advanced glaucoma sometimes requiring reductions of 30% to 40%.

That is why the question surrounding THC is more complicated than simply asking whether it lowers eye pressure. The more important question is whether it can lower IOP enough, reliably enough, and for long enough to protect people with glaucoma.

Study Examines THC and Eye Pressure

Published in the Canadian Journal of Ophthalmology, the research¹ is a systematic review and meta-analysis examining previous studies of THC and intraocular pressure. Rather than relying on the results of one experiment, the researchers pooled available evidence to estimate how much THC affected IOP across studies and delivery methods.

The review included five studies involving 99 patients, 69 of whom received THC exposure or intervention. The researchers examined THC administered through intravenous, oral, and topical routes. This is where the results become especially interesting.

THC Really Can Lower Intraocular Pressure

Across the included studies, THC was associated with a pooled peak IOP reduction of 14.66%. The reduction was statistically significant overall. At first glance, that may sound encouraging. A substance capable of lowering eye pressure by nearly 15% could appear to have genuine therapeutic potential. However, the route of administration made a substantial difference.

Intravenous THC produced the largest pooled peak reduction, at 33.27%. Oral THC produced a much smaller estimated reduction of 10.65%, while topical THC produced an estimated reduction of 9.36%. Importantly, the confidence intervals for the oral and topical results crossed zero, meaning the evidence for those routes was not statistically conclusive.

The researchers also looked at four studies that directly compared THC with a control. In that analysis, THC produced a pooled peak IOP reduction of 6.88%, and the difference from control was not statistically significant. The evidence suggests THC can lower IOP, but its effect compared with control was less convincing.

Why Lowering Eye Pressure Is Not Enough

The biggest challenge is not necessarily whether THC can influence eye pressure. It is whether that effect is practical as a glaucoma treatment. Glaucoma therapies are generally designed to provide sustained and predictable IOP control. Conventional treatments include prostaglandin analogs, beta-blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors, rho kinase inhibitors, and miotics. Some patients need more than one medication to reach their target pressure.

THC presents a different set of challenges. Earlier human research has demonstrated that inhaled THC can lower IOP, but the effect is temporary. One study involving healthy adults found that inhaled THC reduced IOP by as much as 16%, with the reduction persisting for several hours before gradually diminishing. That may be useful for demonstrating biological activity, but glaucoma is a chronic disease requiring long-term pressure management. A treatment that produces a short-lived reduction and also causes systemic effects is difficult to use as a replacement for medications specifically designed for glaucoma.

The Psychoactive Problem With THC

There is another obvious obstacle: THC does not act only on the eye. When THC is inhaled or consumed, it enters the systemic circulation and interacts with cannabinoid receptors throughout the body and brain. Its psychoactive effects can include changes in perception, cognition, and alertness.

That creates an important mismatch. Researchers want the pressure-lowering effect in the eye, but patients do not necessarily want the rest of THC’s effects every time they need to manage their IOP. This is one reason researchers have increasingly explored cannabinoid compounds that can target ocular pathways without producing significant systemic or psychoactive effects.

How Cannabinoids May Affect Eye Pressure

The eye contains components of the endocannabinoid system, including cannabinoid receptors in structures involved in controlling aqueous humor dynamics. Researchers have proposed several mechanisms through which cannabinoids may influence IOP, including changes in aqueous humor production and drainage. Cannabinoid signaling may affect structures such as the trabecular meshwork and Schlemm’s canal, which play important roles in fluid outflow from the eye.

This is where the research becomes particularly promising. If scientists can identify which cannabinoid receptors and signaling pathways are responsible for reducing IOP, they may be able to design drugs that target those pathways more precisely. In other words, the valuable discovery may not be that cannabis can lower eye pressure. It may be that the eye’s cannabinoid system contains therapeutic targets worth developing.

Targeted Cannabinoid Drugs May Be Next

Researchers have already investigated synthetic cannabinoid receptor agonists and other cannabinoid-based compounds as potential ocular treatments. There has also been research exploring formulations designed to improve delivery of cannabinoid compounds directly to ocular tissues while reducing systemic exposure. This approach could potentially address several problems at once, including improving how much of a compound reaches the eye, extending its duration of action, and minimizing unwanted effects elsewhere in the body.

Non-psychoactive cannabinoids and compounds designed to selectively interact with cannabinoid receptors are therefore an important area for future investigation.

THC Is Not a Glaucoma Cure

The meta-analysis should not be interpreted as evidence that people with glaucoma should replace prescribed treatment with cannabis. The study found that THC significantly reduced IOP overall, but the effect was comparatively less compelling against control. The evidence base was also small, consisting of only five studies and 99 total participants.

That matters when interpreting the findings, as a statistically measurable biological effect is not automatically the same thing as an effective clinical treatment. For glaucoma, researchers ultimately need evidence showing that an intervention can provide reliable, sustained pressure control and help preserve vision over time.

There is also an important distinction between lowering IOP and protecting the optic nerve. Although cannabinoid related neuroprotective effects have been proposed, there is not yet clear clinical evidence establishing that THC or cannabis prevents glaucoma-related vision loss through neuroprotection.

What the Research Means for Cannabis

The latest evidence adds an important piece to a decades-old scientific puzzle. THC appears capable of lowering intraocular pressure, confirming that the effect observed in earlier research is not simply a myth surrounding medical cannabis. However, the magnitude, consistency, route-dependent differences, and practical limitations make THC itself an unlikely replacement for established glaucoma medications currently.

The more compelling opportunity may be sitting inside the eye rather than inside the cannabis plant. By studying cannabinoid receptors and the signaling pathways that regulate ocular fluid dynamics, researchers may eventually develop targeted cannabinoid medicines that lower IOP without producing the psychoactive effects associated with THC. That could transform the conversation from, Can cannabis treat glaucoma? to a much more scientifically useful question, Can cannabinoid biology help scientists create better glaucoma medicines?

For now, the evidence points toward possibility rather than proof. THC can lower eye pressure, but the latest research suggests that turning that biological effect into a practical glaucoma treatment will require much more precise and much more targeted medicine.

References:

^{1. Dhivagaran T, Butt F, Mathew D Intraocular pressure-lowering effects of tetrahydrocannabinol drugs: a systematic review and meta-analysis Canadian Journal of Ophthalmology, 2026; 0 https://www.canadianjournalofophthalmology.ca/article/S0008-4182(26)00150-X/fulltext}